Rating Change
HC Wainwright & Co. reiterated its Buy rating on Inhibrx Biosciences, Inc. (NASDAQ:INBX) on November 16, 2026.
HC Wainwright & Co. reiterated its Buy rating on Inhibrx Biosciences, Inc.

At publication ·
Inhibrx Biosciences, Inc. (NASDAQ:INBX) · reiterate
At a glance
HC Wainwright & Co. reiterated its Buy rating on Inhibrx Biosciences, Inc. (NASDAQ:INBX) on November 16, 2026.
Inhibrx Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $77.59 with a market capitalization of $1.2B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Inhibrx Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 16, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 08, 2026 | Stifel | Buy | N/A |
| Aug 22, 2025 | JMP Securities | Market Perform | N/A |
| May 15, 2025 | JMP Securities | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View INBX Stock Page
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Inhibrx Biosciences, Inc. (NASDAQ:INBX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INBX forecast page.
Keep reading
Current market data
NASDAQ · INBX
$83.30
Down: -$5.64 · -6.77%
Live quote updated